BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 15114697)

  • 21. [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
    Nimura H; Mitsumori N; Tsukagoshi S; Nakajima M; Atomi Y; Suzuki S; Kusano M; Yoshiyuki T; Tokunaga A
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1289-96. PubMed ID: 14518408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Results of treatment of far advanced and recurrent stomach cancer with TS-1].
    Johira H; Yunoki S; Kawata N; Watanabe N; Hachisuka Y; Kimura M; Uomoto M; Hatano H; Sanada E; Watanabe R; Ohmori K; Miyata N
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):195-9. PubMed ID: 15751632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma.
    Harada K; Sato M; Ueyama Y; Nagayama M; Hamakawa H; Nagahata S; Yoshimura Y; Osaki T; Ryoke K;
    Anticancer Drugs; 2008 Jan; 19(1):85-90. PubMed ID: 18043133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [S-1 monotherapy for pancreatic cancer].
    Okusaka T; Ueno H; Ikeda M; Morizane C
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():207-12. PubMed ID: 16898004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
    Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
    Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
    Ohtsu A
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():52-6. PubMed ID: 16897972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A late phase II study of S-1 for metastatic pancreatic cancer.
    Okusaka T; Funakoshi A; Furuse J; Boku N; Yamao K; Ohkawa S; Saito H
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):615-21. PubMed ID: 17520253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
    Hara A; Tokuhara T; Takahashi Y; Izumi N; Iwamoto S; Satake K
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):601-4. PubMed ID: 15114708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
    Lee JL; Kang HJ; Kang YK; Ryu MH; Chang HM; Kim TW; Sohn HJ; Kim H; Lee JS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):837-45. PubMed ID: 17579864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
    Saek T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Aoyama H; Ota J; Noguchi S; Taguchi T
    Breast Cancer; 2004; 11(2):194-202. PubMed ID: 15550867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer].
    Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Tsuzuki T; Hirao K; Nakauchi M; Nasu J; Hirasaki S; Endo H; Masumoto T; Tanimizu M; Kubo Y; Kurita A
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):489-94. PubMed ID: 12722679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
    Naito S; Tsukamoto T; Usami M; Fujimoto H; Akaza H
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1065-70. PubMed ID: 20157711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer.
    Totani Y; Saito Y; Hayashi M; Tada T; Kohashi Y; Mieno Y; Kato A; Imizu H; Yoneda Y; Hoshino T; Uchiyama Y; Takeuchi Y; Okazawa M; Sakakibara H
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1181-5. PubMed ID: 19377885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
    Fujitani K; Tsujinaka T; Hirao M
    Hepatogastroenterology; 2003; 50(51):889-92. PubMed ID: 12828112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
    Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
    Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
    Lenz HJ; Lee FC; Haller DG; Singh D; Benson AB; Strumberg D; Yanagihara R; Yao JC; Phan AT; Ajani JA
    Cancer; 2007 Jan; 109(1):33-40. PubMed ID: 17133415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
    Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
    J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study.
    Furuse J; Okusaka T; Boku N; Ohkawa S; Sawaki A; Masumoto T; Funakoshi A
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):849-55. PubMed ID: 18214482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.